Egetis Therapeutics Balance Sheet Health
Financial Health criteria checks 2/6
Egetis Therapeutics has a total shareholder equity of SEK318.6M and total debt of SEK111.2M, which brings its debt-to-equity ratio to 34.9%. Its total assets and total liabilities are SEK577.5M and SEK258.9M respectively.
Key information
34.9%
Debt to equity ratio
SEK 111.20m
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 129.90m |
| Equity | SEK 318.60m |
| Total liabilities | SEK 258.90m |
| Total assets | SEK 577.50m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0ABW's short term assets (SEK164.4M) do not cover its short term liabilities (SEK167.0M).
Long Term Liabilities: 0ABW's short term assets (SEK164.4M) exceed its long term liabilities (SEK91.9M).
Debt to Equity History and Analysis
Debt Level: 0ABW has more cash than its total debt.
Reducing Debt: 0ABW's debt to equity ratio has increased from 0% to 34.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0ABW has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 0ABW has less than a year of cash runway if free cash flow continues to reduce at historical rates of 23.4% each year